Your Messages Inbox
Your Article Summary
See Latest ArticlesMorphotek, Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
Morphotek, 07/17/09
Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, announced that they have entered into an evaluation and option agreement in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Expanding The Biopharmaceutical Industry's Involvement In Fighting Neglected Diseases
Health Affairs, 11/19/09
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Harris Corp. Buys VA Contractor
HealthDataManagement, 11/23/09
Article Search
Sponsor